Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574676 · ClinicalTrials.gov registry record
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
A clinical trial, sponsored by Prothena Biosciences.
- Completed
- Registry status
- 343
- Enrollment target
NCT02574676: Completed study, sponsored by Prothena Biosciences.
NCT02574676 is a clinical trial that has completed, run by Prothena Biosciences. The registered enrollment target is 343 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02574676 has completed, sponsored by Prothena Biosciences.
- COMPLETED
- Registry status
- 343 participants
- Enrollment target
Study Summary
This is an online registry to document the psychometric properties of SF-36v2 among patients with AL Amyloidosis, to document patients' burden of disease, to better understand the patient's experience and to follow quality of life issues using a variety of QOL measures.
Interventions
- OTHER non-interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-07 |
What the finished NCT02574676 record still lists
NCT02574676 is an observational study that tracks outcomes without assigning an intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which non-interventional is the first listed.
NCT02574676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02574676 about?
NCT02574676 is a clinical study titled "Quality of Life (QOL) Registry for Patients With AL Amyloidosis". This is an online registry to document the psychometric properties of SF-36v2 among patients with AL Amyloidosis, to document patients' burden of disease, to better understand the patient's experience and to follow quality of life issues using a variety of QOL measures.
What is the current status of trial NCT02574676?
This trial is currently completed. The enrollment target is 343 participants. The study started on 2015-10. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02574676?
The interventions under investigation include: non-interventional (OTHER).
Who is sponsoring clinical trial NCT02574676?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia